| Summary of Significant Expenses and Other Segment Items |
A summary of the significant expenses and other segment items reported in the Company’s statements of operations as of the dates indicated is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenues |
|
$ |
26,861 |
|
|
$ |
20,018 |
|
|
$ |
52,416 |
|
|
$ |
37,976 |
|
Less: |
|
|
|
|
|
|
|
|
|
|
|
|
Direct costs and expenses (less employee related expenses and depreciation and amortization) |
|
|
3,540 |
|
|
|
3,050 |
|
|
|
6,252 |
|
|
|
5,573 |
|
Employee related expenses (less share-based compensation expenses) |
|
|
19,420 |
|
|
|
16,966 |
|
|
|
38,629 |
|
|
|
31,770 |
|
Contracted services expenses |
|
|
1,692 |
|
|
|
1,858 |
|
|
|
3,381 |
|
|
|
4,180 |
|
Sales and marketing education and event expenses |
|
|
2,235 |
|
|
|
1,983 |
|
|
|
4,446 |
|
|
|
3,852 |
|
Occupancy and equipment service expenses |
|
|
974 |
|
|
|
947 |
|
|
|
1,970 |
|
|
|
1,951 |
|
Clinical trials and associated costs |
|
|
191 |
|
|
|
501 |
|
|
|
829 |
|
|
|
1,003 |
|
Depreciation and amortization expense |
|
|
1,386 |
|
|
|
1,437 |
|
|
|
2,783 |
|
|
|
2,876 |
|
Share-based compensation expenses |
|
|
820 |
|
|
|
1,039 |
|
|
|
1,935 |
|
|
|
2,011 |
|
Interest expense |
|
|
1,982 |
|
|
|
1,898 |
|
|
|
3,959 |
|
|
|
3,583 |
|
Change in fair value of warrant liability, net |
|
|
— |
|
|
|
(98 |
) |
|
|
— |
|
|
|
280 |
|
Other segment items (1) |
|
|
1,894 |
|
|
|
1,905 |
|
|
|
3,298 |
|
|
|
3,466 |
|
Net loss |
|
$ |
(7,273 |
) |
|
$ |
(11,468 |
) |
|
$ |
(15,066 |
) |
|
$ |
(22,569 |
) |
(1)Other segment items in segment net loss primarily include software and IT related expenses, administrative and professional development expenses, risk management and insurance expenses, other non-cash expenses, and allocated overhead expenses.
|